Anti-Mouse CD25 – Purified in vivo GOLD™ Functional Grade

IL-2-dependent cytolytic mouse T-cell clone B6.1

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

CODEX®
B
Depletion
IHC (Frozen)
IP
FA

Clone PC61 recognizes an epitope on mouse CD25.

CD25 is expressed in activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells.

CD25, a 55 kD type I transmembrane glycoprotein, has been shown to play roles in lymphocyte differentiation, activation, and proliferation. Many resting memory T cells constitutively express IL2RA. It functions as the receptor for HTLV-1, resulting in its expression on neoplastic cells in adult T cell lymphoma/leukemia. CD25 (sIL-2R) has been used to track disease progression. Some additional clinical applications include Chagas disease, a disease characterized by a decline of CD25 expression on immune cells, and Multiple sclerosis, in which treatments with mAbs target CD25.

IL-2

Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132)

1.) Braley-Mullen, H. et al. (2018) Immunohorizons. 2(1): 54–66. PubMed
2.) Leonard, WJ. et al. (2002) The EMBO Journal 21: 3051
3.) Alt, FW. et al. (1995) Immnnity 3: 521
4.) Greene, WC. et al. (1990) J Invest Dermatol. 94: 27S
5.) Gubin, M. et al. (2018) Cell. 175(4):1014–1030.e19 Journal Link